Company intelligence / Profile preview

IntraBio

Ownership: Private
Development stage: Other

Overview

IntraBio has achieved FDA approval for AQNEURSA (modified amino acid) to treat neurological manifestations of Niemann-Pick type C. Its lead program IB1001 completed a pivotal Phase III trial in mid-June 2023. The company’s pipeline includes additional assets targeting rare and common neurodegenerative diseases. Clinical results have been published in leading medical journals; the company has moved its HQ from Oxford, UK to Austin, Texas.

Therapeutic areas: Rare DiseasesNeurology
Modalities: Small molecules (notably modified amino acids such as N-Acetyl-L-Leucine)
Industry: Biotech

Drug pipeline

7 assets

levacetylleucine

Approved

6 more assets in the full pipeline.

Partnerships

None specifically named; collaborations with academic institutions are noted.

Beyond the preview

Go deeper on IntraBio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IntraBio.